Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, said:
“It's fantastic to see that trastuzumab deruxtecan (Enhertu) could give hundreds of people with HER2 positive incurable secondary breast cancer the chance of more time before their disease progresses.
“These are incredibly promising results. We now hope that further research will show whether this treatment could also offer patients precious extra time to live and to be there for more moments that matter.
“We look forward to Enhertu being submitted for licensing in this new indication.1
"Anyone looking for support and information can speak to Breast Cancer Now’s expert nurses by calling our free Helpline on 0808 800 6000.”
ENDS
Notes to editors
- Enhertu is currently licensed for patients who have already had two or more other treatments specifically for this type of breast cancer.
About Breast Cancer Now
- Breast Cancer Now is the UK’s first comprehensive breast cancer charity, combining world-class research and life-changing care.
- Breast Cancer Now’s ambition is that, by 2050, everyone who develops breast cancer will live and be supported to live well.
- Breast Cancer Now, the research and care charity, launched in October 2019, created by the merger of specialist support and information charity Breast Cancer Care and leading research charity Breast Cancer Now.
- Visit breastcancernow.org or follow us on Twitter or Facebook or Instagram
- Anyone looking for support or information can call Breast Cancer Now’s free Helpline on 0808 800 6000.